Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
A phase 1/2 trial of JSKN003 in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, active and no longer recruiting.
Overview
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05744427 by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, with 725 participants enrolled, started 2023-03-15 and due to reach its primary completion in 2026-07-30. Interventions recorded: JSKN003.
Similar pages
not linked directly; found by shared links- TrialStudy of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Shares Alphamab Oncology, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Shares JSKN003, Alphamab Oncology.
- TreatmentJSKN016
Shares Alphamab Oncology and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.